BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30565388)

  • 1. Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding.
    Slobodianuk TL; Kochelek C; Foeckler J; Kalloway S; Weiler H; Flood VH
    J Thromb Haemost; 2019 Jan; 17(1):63-71. PubMed ID: 30565388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crucial role for the VWF A1 domain in binding to type IV collagen.
    Flood VH; Schlauderaff AC; Haberichter SL; Slobodianuk TL; Jacobi PM; Bellissimo DB; Christopherson PA; Friedman KD; Gill JC; Hoffmann RG; Montgomery RR;
    Blood; 2015 Apr; 125(14):2297-304. PubMed ID: 25662333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
    Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
    J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The physical spacing between the von Willebrand factor D'D3 and A1 domains regulates platelet adhesion in vitro and in vivo.
    Zhang C; Kelkar A; Nasirikenari M; Lau JTY; Sveinsson M; Sharma UC; Pokharel S; Neelamegham S
    J Thromb Haemost; 2018 Mar; 16(3):571-582. PubMed ID: 29251812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
    Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
    J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.
    Adam F; Casari C; Prévost N; Kauskot A; Loubière C; Legendre P; Repérant C; Baruch D; Rosa JP; Bryckaert M; de Groot PG; Christophe OD; Lenting PJ; Denis CV
    Sci Rep; 2016 May; 6():26306. PubMed ID: 27212476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
    De Meyer SF; Vandeputte N; Pareyn I; Petrus I; Lenting PJ; Chuah MK; VandenDriessche T; Deckmyn H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1621-6. PubMed ID: 18556568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional studies on platelet adhesion with recombinant von Willebrand factor type 2B mutants R543Q and R543W under conditions of flow.
    Lankhof H; Damas C; Schiphorst ME; IJsseldijk MJ; Bracke M; Sixma JJ; Vink T; de Groot PG
    Blood; 1997 Apr; 89(8):2766-72. PubMed ID: 9108394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis.
    Denis C; Methia N; Frenette PS; Rayburn H; Ullman-Culleré M; Hynes RO; Wagner DD
    Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9524-9. PubMed ID: 9689113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W.
    Pruss CM; Golder M; Bryant A; Hegadorn C; Haberichter S; Lillicrap D
    J Thromb Haemost; 2012 May; 10(5):940-50. PubMed ID: 22372972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa.
    Marx I; Christophe OD; Lenting PJ; Rupin A; Vallez MO; Verbeuren TJ; Denis CV
    Blood; 2008 Aug; 112(3):603-9. PubMed ID: 18487513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction of von Willebrand factor-A1 domain with collagen: mutation G1324S (type 2M von Willebrand disease) impairs the conformational change in A1 domain induced by collagen.
    Morales LD; Martin C; Cruz MA
    J Thromb Haemost; 2006 Feb; 4(2):417-25. PubMed ID: 16420575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation.
    Guerrero JA; Kyei M; Russell S; Liu J; Gartner TK; Storrie B; Ware J
    Blood; 2009 Dec; 114(27):5541-6. PubMed ID: 19808696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor.
    Shinagawa A; Kojima H; Berndt MC; Kaneko S; Suzukawa K; Hasegawa Y; Shigeta O; Nagasawa T
    Thromb Haemost; 2005 May; 93(5):889-96. PubMed ID: 15886805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24.
    Bowman ML; Pluthero FG; Tuttle A; Casey L; Li L; Christensen H; Robinson KS; Lillicrap D; Kahr WHA; James P
    J Thromb Haemost; 2017 Jul; 15(7):1403-1411. PubMed ID: 28453889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical von Willebrand factor A1 domain residues influence type VI collagen binding.
    Flood VH; Gill JC; Christopherson PA; Bellissimo DB; Friedman KD; Haberichter SL; Lentz SR; Montgomery RR
    J Thromb Haemost; 2012 Jul; 10(7):1417-24. PubMed ID: 22507569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease.
    Roussi J; Turecek PL; André P; Bonneau M; Pignaud G; Bal dit Sollier C; Schlokat U; Dorner F; Schwarz HP; Drouet L
    Blood Coagul Fibrinolysis; 1998 Jun; 9(4):361-72. PubMed ID: 9690808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.